CR
Cardiff Oncology, Inc.
CRDF · NASDAQ
$1.08 +1.89% (+$0.02)
1M -10.74%
Market Cap $81.7M
P/E Ratio -
Div. Yield -
ROE 103.08%
Bulios Fair Price
$1.52
40.7% upside
Current Price
$1.08
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CRDF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
33 /100
Expensive P/B 3.08x
P/S 160.82x
P/FFO N/A
Growth
69 /100
Growing Book val. growth 24.71%
Rev. growth 15.39%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 8,320.08%
Gross margin 100.00%
FCF margin 8,054.33%
Quality
0 /100
Poor ROA 107.29%
ROIC 156.61%
Asset turnover 0.01x
Debt
100 /100
Low Current ratio 3.30x
Debt/Equity 0.02x
Debt/Assets N/A
Stability
49 /100
Moderate EPS volatility 17.76%
Beta 1.42x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CRDF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mani Mohindru
Employees
31
Headquarters
San Diego
Upcoming events
05 NOV
Earnings
Upcoming earnings report